Zsu-Zsu Chen

Dr. Zsu-Zsu Chen

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Neuron
Verified
Journal Article
Closed access
XLXian Lin
Xian Lin
LPLoukia Parisiadou
Loukia Parisiadou
XGXing-Long Gu
Xing-Long Gu
LWLizhen Wang
Lizhen Wang
HSHoon Shim
Hoon Shim
HCHuaibin Cai
Huaibin Cai

19 August 2022 in Science Advances
Verified
Journal Article
Open access
DKDaniel H. Katz
Daniel H. Katz
JRJeremy M. Robbins
Jeremy M. Robbins
SDShuliang Deng
Shuliang Deng
UTUsman A. Tahir
Usman A. Tahir
ABAlexander G. Bick
Alexander G. Bick
RGRobert Edgardo Gerszten
Robert Edgardo Gerszten
High-throughput proteomic profiling using antibody or aptamer-based affinity reagents is used increasingly in human studies. However, direct analyses to address the relative strengths and weaknesses of these platforms are lacking. We assessed findings from the SomaScan1.3K ( N = 1301 reagents), the SomaScan5K platform ( N = 4979 reagents), and the Olink Explore ( N = 1472 reagents) profiling techniques in 568 adults from the Jackson Heart Study and 219 participants in the HERITAGE Family Study across four performance domains: precision, accuracy, analytic breadth, and phenotypic associations leveraging detailed clinical phenotyping and genetic data. Across these studies, we show evidence supporting more reliable protein target specificity and a higher number of phenotypic associations for the Olink platform, while the Soma platforms benefit from greater measurement precision and analytic breadth across the proteome.

18 March 2024 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SXShuke Xiao
Shuke Xiao
VLVeronica L. Li
Veronica L. Li
XLXuchao Lyu
Xuchao Lyu
XCXudong Chen
Xudong Chen
WWWei Wei
Wei Wei
JLJonathan Z. Long
Jonathan Z. Long

8 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
DNDebby Ngo
Debby Ngo
MBMark Benson
Mark Benson
JLJonathan Z. Long
Jonathan Z. Long
ZCZsu-Zsu Chen
Zsu-Zsu Chen
RWRuiqi Wang
Ruiqi Wang
RGRobert Edgardo Gerszten
Robert Edgardo Gerszten
Recent advances in proteomic technologies have made high-throughput profiling of low-abundance proteins in large epidemiological cohorts increasingly feasible. We investigated whether aptamer-based proteomic profiling could identify biomarkers associated with future development of type 2 diabetes (T2DM) beyond known risk factors. We identified dozens of markers with highly significant associations with future T2DM across 2 large longitudinal cohorts ( n = 2839) followed for up to 16 years. We leveraged proteomic, metabolomic, genetic, and clinical data from humans to nominate 1 specific candidate to test for potential causal relationships in model systems. Our studies identified functional effects of aminoacylase 1 (ACY1), a top protein association with future T2DM risk, on amino acid metabolism and insulin homeostasis in vitro and in vivo. Furthermore, a loss-of-function variant associated with circulating levels of the biomarker WAP, Kazal, immunoglobulin, Kunitz, and NTR domain–containing protein 2 (WFIKKN2) was, in turn, associated with fasting glucose, hemoglobin A1c, and HOMA-IR measurements in humans. In addition to identifying potentially novel disease markers and pathways in T2DM, we provide publicly available data to be leveraged for insights about gene function and disease pathogenesis in the context of human metabolism.

19 January 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
UTUsman A. Tahir
Usman A. Tahir
DKDaniel H. Katz
Daniel H. Katz
TZTianyi Zhao
Tianyi Zhao
DNDebby Ngo
Debby Ngo
DCDaniel E. Cruz
Daniel E. Cruz
RGRobert Edgardo Gerszten
Robert Edgardo Gerszten
Background: Heart failure (HF) is a heterogeneous disease characterized by significant metabolic disturbances; however, the breadth of metabolic dysfunction before the onset of overt disease is not well understood. The purpose of this study was to determine the association of circulating metabolites with incident HF to uncover novel metabolic pathways to disease. Methods: We performed targeted plasma metabolomic profiling in a deeply phenotyped group of Black adults from the JHS (Jackson Heart Study; n=2199). We related metabolites associated with incident HF to established etiological mechanisms, including increased left ventricular mass index and incident coronary heart disease. Furthermore, we evaluated differential associations of metabolites with HF with preserved ejection fraction versus HF with reduced ejection fraction. Results: Metabolites associated with incident HF included products of posttranscriptional modifications of RNA, as well as polyamine and nitric oxide metabolism. A subset of metabolite-HF associations was independent of well-established HF pathways such as increased left ventricular mass index and incident coronary heart disease and included homoarginine (per 1 SD increase in metabolite level, hazard ratio, 0.77; P =1.2×10 −3 ), diacetylspermine (hazard ratio, 1.34; P =3.4×10 −3 ), and uridine (hazard ratio, 0.79; P , 3×10 −4 ). Furthermore, metabolites involved in pyrimidine metabolism (orotic acid) and collagen turnover ( N -methylproline) among others were part of a distinct metabolic signature that differentiated individuals with HF with preserved ejection fraction versus HF with reduced ejection fraction. Conclusions: The integration of clinical phenotyping with plasma metabolomic profiling uncovered novel metabolic processes in nontraditional disease pathways underlying the heterogeneity of HF development in Black adults.

3 October 2019 in Diabetes
Verified
Journal Article
Open access
PDF file
ZCZsu-Zsu Chen
Zsu-Zsu Chen
JLJinxi Liu
Jinxi Liu
JMJordan Morningstar
Jordan Morningstar
BHBrandy M. Heckman-Stoddard
Brandy M. Heckman-Stoddard
CLChristine G. Lee
Christine G. Lee
DGDiabetes Prevention Program Research Group
Diabetes Prevention Program Research Group
Novel biomarkers of type 2 diabetes (T2D) and response to preventative treatment in individuals with similar clinical risk may highlight metabolic pathways that are important in disease development. We profiled 331 metabolites in 2,015 baseline plasma samples from the Diabetes Prevention Program (DPP). Cox models were used to determine associations between metabolites and incident T2D, as well as whether associations differed by treatment group (i.e., lifestyle [ILS], metformin [MET], or placebo [PLA]), over an average of 3.2 years of follow-up. We found 69 metabolites associated with incident T2D regardless of treatment randomization. In particular, cytosine was novel and associated with the lowest risk. In an exploratory analysis, 35 baseline metabolite associations with incident T2D differed across the treatment groups. Stratification by baseline levels of several of these metabolites, including specific phospholipids and AMP, modified the effect that ILS or MET had on diabetes development. Our findings highlight novel markers of diabetes risk and preventative treatment effect in individuals who are clinically at high risk and motivate further studies to validate these interactions.